2022
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma
Talia K, Banet N, Buza N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 2022, 55: 8-18. PMID: 36503635, DOI: 10.1016/j.pathol.2022.11.004.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousBiomarkers, TumorEndometrial NeoplasmsFemaleHumansMolecular Targeted TherapyReceptor, ErbB-2ConceptsHuman epidermal growth factor receptor 2Uterine serous carcinomaRole of HER2Serous carcinomaClinical trialsHER2 overexpressionPrognostic biomarkerTherapeutic targetHigh-grade endometrioid carcinomaEpidermal growth factor receptor 2Vulvar Paget's diseaseGrowth factor receptor 2Time of diagnosisFuture clinical trialsGynaecological cancer careClinical trial dataHER2 protein overexpressionFactor receptor 2P53 mutant tumorsRecurrent diseaseSurvival benefitGynaecological malignanciesPaget's diseaseClinical benefitEndometrial carcinoma
2019
Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls
Buza N. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. Archives Of Pathology & Laboratory Medicine 2019, 143: 47-64. PMID: 30785337, DOI: 10.5858/arpa.2018-0289-ra.Peer-Reviewed Original ResearchConceptsFrozen section evaluationOvarian epithelial tumorsIntraoperative frozen section evaluationFrozen section diagnosisEpithelial tumorsOvarian tumorsSection evaluationSection diagnosisClear cell ovarian tumorsExtensive staging proceduresExtent of surgeryCareful gross examinationPreoperative diagnostic workupCommon clinical scenariosAccurate frozen section diagnosisSignificant diagnostic challengePotential diagnostic pitfallFrozen section laboratorySurgical stagingStaging procedureYounger patientsBorderline tumorsSerum markersOvarian massesDiagnostic challenge